| . | Total Population (n = 115) . | Toxicity Group (n = 24) . | Nontoxicity Group (n = 91) . | P Value . |
|---|---|---|---|---|
| Age, y | 54 [37–64] | 55 [45–66] | 52 [35–64] | .39 |
| Male | 55 (47.8) | 9 (37.5) | 45 (50.5) | .26 |
| Comorbid conditions | ||||
| Obese | 55 (47.8) | 16 (66.7) | 38 (42.9) | .04 |
| Diabetes | 35 (30.4) | 6 (25) | 29 (31.9) | .52 |
| Dyslipidemia | 15 (13) | 5 (20.8) | 10 (11) | .30 |
| Hypertension | 62 (53.9) | 16 (66.7) | 46 (50.5) | .35 |
| Heart failure | 8 (7) | 3 (12.5) | 5 (5.5) | .36 |
| Chronic kidney disease | 12 (10.4) | 3 (12.5) | 9 (9.9) | .71 |
| Cancer | 64 (55.7) | 11 (45.58) | 53 (58.2) | .28 |
| Renal transplant | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Concomitant nephrotoxic agents | ||||
| ACE inhibitors | 17 (14.8) | 6 (25) | 11 (12.1) | .19 |
| Aminoglycosides | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Amphotericin | 4 (3.5) | 1 (4.3) | 3 (3.3) | 1.00 |
| Contrast dye | 27 (23.5) | 8 (33.3) | 19 (20.9) | .20 |
| Loop diuretics | 23 (20) | 6 (25) | 17 (18.7) | .57 |
| NSAIDs | 11 (9.6) | 2 (8.3) | 9 (9.9) | 1.00 |
| Vancomycin | 63 (54.8) | 19 (79.2) | 44 (48.4) | .04 |
| Concomitant fluids | 94 (81.7) | 21 (87.5) | 73 (80.2) | .56 |
| Baseline serum creatinine, mg/dL | 0.73 [0.6–1.1] | 0.6 [0.5–0.8] | 0.8 [0.6–1.1] | .07 |
| Highest serum creatinine, mg/dL | 0.98 [0.7–1.3] | 1.9 [1.1–3] | 0.9 [0.7–1.2] | <.001 |
| Day of highest serum creatinine, mg/dL | 4 [2–5] | 4.5 [3–7] | 3 [1–5] | .003 |
| Admission weight, kg | 79.5 [67–98] | 89.9 [67–120] | 79.1 [67–95] | .18 |
| . | Total Population (n = 115) . | Toxicity Group (n = 24) . | Nontoxicity Group (n = 91) . | P Value . |
|---|---|---|---|---|
| Age, y | 54 [37–64] | 55 [45–66] | 52 [35–64] | .39 |
| Male | 55 (47.8) | 9 (37.5) | 45 (50.5) | .26 |
| Comorbid conditions | ||||
| Obese | 55 (47.8) | 16 (66.7) | 38 (42.9) | .04 |
| Diabetes | 35 (30.4) | 6 (25) | 29 (31.9) | .52 |
| Dyslipidemia | 15 (13) | 5 (20.8) | 10 (11) | .30 |
| Hypertension | 62 (53.9) | 16 (66.7) | 46 (50.5) | .35 |
| Heart failure | 8 (7) | 3 (12.5) | 5 (5.5) | .36 |
| Chronic kidney disease | 12 (10.4) | 3 (12.5) | 9 (9.9) | .71 |
| Cancer | 64 (55.7) | 11 (45.58) | 53 (58.2) | .28 |
| Renal transplant | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Concomitant nephrotoxic agents | ||||
| ACE inhibitors | 17 (14.8) | 6 (25) | 11 (12.1) | .19 |
| Aminoglycosides | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Amphotericin | 4 (3.5) | 1 (4.3) | 3 (3.3) | 1.00 |
| Contrast dye | 27 (23.5) | 8 (33.3) | 19 (20.9) | .20 |
| Loop diuretics | 23 (20) | 6 (25) | 17 (18.7) | .57 |
| NSAIDs | 11 (9.6) | 2 (8.3) | 9 (9.9) | 1.00 |
| Vancomycin | 63 (54.8) | 19 (79.2) | 44 (48.4) | .04 |
| Concomitant fluids | 94 (81.7) | 21 (87.5) | 73 (80.2) | .56 |
| Baseline serum creatinine, mg/dL | 0.73 [0.6–1.1] | 0.6 [0.5–0.8] | 0.8 [0.6–1.1] | .07 |
| Highest serum creatinine, mg/dL | 0.98 [0.7–1.3] | 1.9 [1.1–3] | 0.9 [0.7–1.2] | <.001 |
| Day of highest serum creatinine, mg/dL | 4 [2–5] | 4.5 [3–7] | 3 [1–5] | .003 |
| Admission weight, kg | 79.5 [67–98] | 89.9 [67–120] | 79.1 [67–95] | .18 |
Data are presented as No. (%) or median [interquartile range].
Abbreviations: ACE, angiotensin-converting enzyme; NSAID, nonsteroidal anti-inflammatory drug.
| . | Total Population (n = 115) . | Toxicity Group (n = 24) . | Nontoxicity Group (n = 91) . | P Value . |
|---|---|---|---|---|
| Age, y | 54 [37–64] | 55 [45–66] | 52 [35–64] | .39 |
| Male | 55 (47.8) | 9 (37.5) | 45 (50.5) | .26 |
| Comorbid conditions | ||||
| Obese | 55 (47.8) | 16 (66.7) | 38 (42.9) | .04 |
| Diabetes | 35 (30.4) | 6 (25) | 29 (31.9) | .52 |
| Dyslipidemia | 15 (13) | 5 (20.8) | 10 (11) | .30 |
| Hypertension | 62 (53.9) | 16 (66.7) | 46 (50.5) | .35 |
| Heart failure | 8 (7) | 3 (12.5) | 5 (5.5) | .36 |
| Chronic kidney disease | 12 (10.4) | 3 (12.5) | 9 (9.9) | .71 |
| Cancer | 64 (55.7) | 11 (45.58) | 53 (58.2) | .28 |
| Renal transplant | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Concomitant nephrotoxic agents | ||||
| ACE inhibitors | 17 (14.8) | 6 (25) | 11 (12.1) | .19 |
| Aminoglycosides | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Amphotericin | 4 (3.5) | 1 (4.3) | 3 (3.3) | 1.00 |
| Contrast dye | 27 (23.5) | 8 (33.3) | 19 (20.9) | .20 |
| Loop diuretics | 23 (20) | 6 (25) | 17 (18.7) | .57 |
| NSAIDs | 11 (9.6) | 2 (8.3) | 9 (9.9) | 1.00 |
| Vancomycin | 63 (54.8) | 19 (79.2) | 44 (48.4) | .04 |
| Concomitant fluids | 94 (81.7) | 21 (87.5) | 73 (80.2) | .56 |
| Baseline serum creatinine, mg/dL | 0.73 [0.6–1.1] | 0.6 [0.5–0.8] | 0.8 [0.6–1.1] | .07 |
| Highest serum creatinine, mg/dL | 0.98 [0.7–1.3] | 1.9 [1.1–3] | 0.9 [0.7–1.2] | <.001 |
| Day of highest serum creatinine, mg/dL | 4 [2–5] | 4.5 [3–7] | 3 [1–5] | .003 |
| Admission weight, kg | 79.5 [67–98] | 89.9 [67–120] | 79.1 [67–95] | .18 |
| . | Total Population (n = 115) . | Toxicity Group (n = 24) . | Nontoxicity Group (n = 91) . | P Value . |
|---|---|---|---|---|
| Age, y | 54 [37–64] | 55 [45–66] | 52 [35–64] | .39 |
| Male | 55 (47.8) | 9 (37.5) | 45 (50.5) | .26 |
| Comorbid conditions | ||||
| Obese | 55 (47.8) | 16 (66.7) | 38 (42.9) | .04 |
| Diabetes | 35 (30.4) | 6 (25) | 29 (31.9) | .52 |
| Dyslipidemia | 15 (13) | 5 (20.8) | 10 (11) | .30 |
| Hypertension | 62 (53.9) | 16 (66.7) | 46 (50.5) | .35 |
| Heart failure | 8 (7) | 3 (12.5) | 5 (5.5) | .36 |
| Chronic kidney disease | 12 (10.4) | 3 (12.5) | 9 (9.9) | .71 |
| Cancer | 64 (55.7) | 11 (45.58) | 53 (58.2) | .28 |
| Renal transplant | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Concomitant nephrotoxic agents | ||||
| ACE inhibitors | 17 (14.8) | 6 (25) | 11 (12.1) | .19 |
| Aminoglycosides | 1 (0.9) | 0 (0) | 1 (1.1) | 1.00 |
| Amphotericin | 4 (3.5) | 1 (4.3) | 3 (3.3) | 1.00 |
| Contrast dye | 27 (23.5) | 8 (33.3) | 19 (20.9) | .20 |
| Loop diuretics | 23 (20) | 6 (25) | 17 (18.7) | .57 |
| NSAIDs | 11 (9.6) | 2 (8.3) | 9 (9.9) | 1.00 |
| Vancomycin | 63 (54.8) | 19 (79.2) | 44 (48.4) | .04 |
| Concomitant fluids | 94 (81.7) | 21 (87.5) | 73 (80.2) | .56 |
| Baseline serum creatinine, mg/dL | 0.73 [0.6–1.1] | 0.6 [0.5–0.8] | 0.8 [0.6–1.1] | .07 |
| Highest serum creatinine, mg/dL | 0.98 [0.7–1.3] | 1.9 [1.1–3] | 0.9 [0.7–1.2] | <.001 |
| Day of highest serum creatinine, mg/dL | 4 [2–5] | 4.5 [3–7] | 3 [1–5] | .003 |
| Admission weight, kg | 79.5 [67–98] | 89.9 [67–120] | 79.1 [67–95] | .18 |
Data are presented as No. (%) or median [interquartile range].
Abbreviations: ACE, angiotensin-converting enzyme; NSAID, nonsteroidal anti-inflammatory drug.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
